Navigation Links
Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
Date:6/14/2013

PITTSBURGH, June 14, 2013 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG) today announced a reduction in staff and levels of investment that were necessitated by delays in portfolio company exits caused primarily by the current overall investment climate and the uncertainty of state funding.

PLSG President and CEO, John W. Manzetti said, "As the region's only pure life sciences investment firm, the actions taken this week, which were approved by the PLSG Board of Directors, were necessary to protect the future of both our base economic development activities and our investments in both the PLSG and PLSG Accelerator Fund companies.

"These actions will remove expenses related to community and company support and services but still enable us to focus on investments. As our strong portfolio of companies achieve their awaited exits, the PLSG will return to historic levels of annual investment. We have centered our focus on the PLSG's premier Executive Program and have protected our ability to invest modestly until these returns are realized.  Our experienced and highly-focused investment team remains passionate and committed to the growth of the region's important life sciences sector."

About Pittsburgh Life Sciences Greenhouse (PLSG) (www.plsg.com)
The PLSG invests in and supports the growth of biosciences companies in western Pennsylvania. PLSG has a track record of excellence when it comes to attracting and growing life sciences companies in the region. Since its inception in 2001, PLSG has assisted more than 400 life sciences companies and has helped create or retain nearly 6,000 jobs in western Pennsylvania. Thirty-four companies have been provided with office or laboratory space and 13 have been relocated to Pittsburgh from outside of the region. In addition, the PLSG has invested $18.9 million in 76 companies which has leveraged nearly $900 million in additional capital to the region.

About PLSG Accelerator Fund (www.acceleratorfund.com )
The PLSG Accelerator Fund I, which had its final closing in December, 2012 at $8.1 million, currently is fully invested in eight portfolio companies.  The Accelerator Fund provides regional life sciences companies with venture capital financing, which is the next step beyond capital provided by economic development organizations; friends and family; and angel investors.  The Accelerator Fund is building a portfolio of early-stage life sciences investments, primarily located in western Pennsylvania and spread across several life sciences investments, primarily located in western Pennsylvania and spread across several life sciences sectors including medical devices, diagnostics, therapeutics, healthcare information technology and biotechnology tools.  The value proposition of the Fund is at least two-fold: (1) PLSG executive manage the Fund, affording investors with quality of personnel that likely would be otherwise available only through significantly larger funds; (2) only companies that have already performed successfully using PLSG investments and programs are considered for Fund investment.


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
2. The Pittsburgh Life Sciences Greenhouse Congratulates Dr. Paul L. Kornblith, M.D., on Being Named the 2013 recipient of the Schoemaker Award
3. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
4. Pittsburghs Positive Investment Growth Bucks National Trends According to Ernst & Young and Innovation Works Report
5. Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device
6. Garage Start-ups Now Possible in Life Sciences Industry
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. DiaTech Life Sciences Announces Medical Advisory Board
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... From ... innovation is taking over sports. On Thursday, December 15th a panel of entrepreneurs, ... disrupting the playing field at a Smart Talk session. Smart Talk will run ...
(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):